| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-06-2025 | 06-30-2025 | 10-Q | |
| 2 | 05-06-2025 | 03-31-2025 | 10-Q | |
| 3 | 03-20-2025 | 12-31-2024 | 10-K | |
| 4 | 11-07-2024 | 09-30-2024 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available sm...
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.45)...
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benef...
Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate disco...
IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year endBGE-102 induced weight loss in preclinical obe...
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.53) b...
Citigroup analyst Samantha Semenkow maintains Bioage Labs (NASDAQ:BIOA) with a Neutral and lowers the price target from $7 t...
Full Year 2024 Financial ResultsResearch and development expenses were $59.0 million for the year ended December 31, 2024, comp...
Morgan Stanley analyst Jeffrey Hung assumes Bioage Labs (NASDAQ:BIOA) with a Underweight rating and announces Price Target o...
